Research ArticleArticle
γ-Glutamyl Hydrolase from Human Sarcoma HT-1080 Cells: Characterization and Inhibition by Glutamine Antagonists
Mark C. Waltham, Wei-Wei Li, Helena Gritsman, William P. Tong and Joseph R. Bertino
Molecular Pharmacology May 1997, 51 (5) 825-832; DOI: https://doi.org/10.1124/mol.51.5.825
Mark C. Waltham
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Wei-Wei Li
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Helena Gritsman
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
William P. Tong
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Joseph R. Bertino
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
γ-Glutamyl Hydrolase from Human Sarcoma HT-1080 Cells: Characterization and Inhibition by Glutamine Antagonists
Mark C. Waltham, Wei-Wei Li, Helena Gritsman, William P. Tong and Joseph R. Bertino
Molecular Pharmacology May 1, 1997, 51 (5) 825-832; DOI: https://doi.org/10.1124/mol.51.5.825
Research ArticleArticle
γ-Glutamyl Hydrolase from Human Sarcoma HT-1080 Cells: Characterization and Inhibition by Glutamine Antagonists
Mark C. Waltham, Wei-Wei Li, Helena Gritsman, William P. Tong and Joseph R. Bertino
Molecular Pharmacology May 1, 1997, 51 (5) 825-832; DOI: https://doi.org/10.1124/mol.51.5.825
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement